Results 1 to 10 of about 9,024 (141)

A Contemporary Risk Analysis of Iatrogenic Transmission of Creutzfeldt-Jakob Disease (CJD) via Corneal Transplantation in the United States

Ophthalmology and Therapy, 2020
Background Creutzfeldt-Jakob disease (CJD) is a rare, fatal, neurodegenerative prion disease potentially transmissible through corneal transplantation.
Phillip C Hoopes, Yasmyne C Ronquillo, Majid Moshirfar   +2 more
exaly   +2 more sources

Electroencephalography distinguished anti-N-methyl-D-aspartate receptor encephalitis and Creutzfeldt-Jakob disease [PDF]

Frontiers in Neurology
Creutzfeldt-Jakob disease (CJD) and anti-NMDA receptor (anti-NMDAR) encephalitis are two diseases with different progression and prognosis, so it is crucial to distinguish them early.
Jia-Yin Miao, Jing-Zhen Chen, Jing-Zhen Chen, Jian-Qi Zeng, Jian-Qi Zeng, Xin-Yuan Zhao, Yi-Qian Chen, Ru Wang, Feng Wang, Jia-Meng Dong   +9 more
doaj   +2 more sources

Is there a link between COVID-19 and Creutzfeldt-Jakob Disease? a Case Report [PDF]

Journal of Research in Clinical Medicine, 2021
Creutzfeldt-Jakob Disease (CJD) is a rare rapidly progressive neurodegenerative disease. The diagnosis of CJD is based on magnetic resonance imaging (MRI) findings, electro-encephalography (EEG), or 14-3-3 protein detection.
Ehsan Nasiri, Amirreza Naseri, Mohammad Yazdchi, Mahnaz Talebi   +3 more
doaj   +1 more source

Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer’s Disease

Viruses, 2022
Background: CSF total-tau (t-tau) became a standard cerebrospinal fluid biomarker in Alzheimer’s disease (AD). In parallel, extremely elevated levels were observed in Creutzfeldt-Jakob disease (CJD).
Peter Hermann, Philip Haller, Stefan Goebel, Timothy Bunck, Christian Schmidt, Jens Wiltfang, Inga Zerr   +6 more
doaj   +1 more source

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

Alzheimer’s Research & Therapy, 2023
Background Rapidly progressive forms of Alzheimer’s disease (rpAD) are increasingly recognized and may have a prevalence of up to 30% of patients among all patients with Alzheimer’s disease (AD).
Janne Marieke Herden, Peter Hermann, Isabel Schmidt, Kathrin Dittmar, Sezgi Canaslan, Luise Weglage, Sabine Nuhn, Corinna Volpers, Astrid Schlung, Stefan Goebel, Fabian Kück, Anna Villar-Piqué, Christian Schmidt, Dirk Wedekind, Inga Zerr   +14 more
doaj   +1 more source

A clinicopathological study of selected cognitive impairment cases in Lothian, Scotland: enhanced CJD surveillance in the 65 + population group

BMC Geriatrics, 2022
Background Variant Creutzfeldt-Jakob Disease (vCJD) is primarily associated with dietary exposure to bovine-spongiform-encephalopathy. Cases may be missed in the elderly population where dementia is common with less frequent referral to specialist ...
Lovney Kanguru, Gemma Logan, Briony Waddel, Colin Smith, Anna Molesworth, Richard Knight   +5 more
doaj   +1 more source

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers

Alzheimer’s Research & Therapy, 2022
Background Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s disease in reactive microglia and
Peter Hermann, Anna Villar-Piqué, Matthias Schmitz, Christian Schmidt, Daniela Varges, Stefan Goebel, Timothy Bunck, Hanna Lindemann, Carla Bogner, Isabel Santana, Inês Baldeiras, Joachim Riggert, Inga Zerr, Franc Llorens   +13 more
doaj   +1 more source

Plasma YKL-40 in the spectrum of neurodegenerative dementia

Journal of Neuroinflammation, 2019
Background Increased plasma YKL-40 has been reported in Alzheimer’s disease (AD), but its levels in other neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of neurodegenerative dementias.
Anna Villar-Piqué, Matthias Schmitz, Peter Hermann, Stefan Goebel, Timothy Bunck, Daniela Varges, Isidre Ferrer, Joachim Riggert, Franc Llorens, Inga Zerr   +9 more
doaj   +1 more source

Case report: Two clusters of Creutzfeldt–Jakob disease cases within 1 year in West Michigan

Frontiers in Neurology, 2023
BackgroundCreutzfeldt–Jakob disease (CJD) is a rare, rapidly progressive, and uniformly fatal neurodegenerative disease. The reported incidence of CJD is 1 to 2 per million people worldwide annually, with fewer than 1,000 cases in the United States per ...
Ling Ling Rong, Nicholas J. Lannen, Evan C. Tank, Jessica L. Feistel, Christopher J. Therasse, Anvita Potluri, Muhib Khan, Jiangyong Min   +7 more
doaj   +1 more source

Study protocol for enhanced CJD surveillance in the 65+ years population group in Scotland: an observational neuropathological screening study of banked brain tissue donations for evidence of prion disease

BMJ Open, 2019
Introduction Creutzfeldt-Jakob disease (CJD) is a human prion disease that occurs in sporadic, genetic and acquired forms. Variant CJD (vCJD) is an acquired form first identified in 1996 in the UK. To date, 178 cases of vCJD have been reported in the UK,
Colin Smith, Alexander Howard Peden, Lovney Kanguru, Diane L Ritchie, Anna M Molesworth   +4 more
doaj   +1 more source